Insider Selling: Keith Klein Sells 4,500 Shares of KYTHERA Biopharmaceuticals Stock (KYTH)
KYTHERA Biopharmaceuticals (NASDAQ:KYTH) General Counsel Keith Klein sold 4,500 shares of the stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $32.00, for a total value of $144,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link.
KYTH has been the subject of a number of recent research reports. Analysts at Cowen and Company initiated coverage on shares of KYTHERA Biopharmaceuticals (NASDAQ:KYTH) in a research note to investors on Friday. They set an “outperform” rating and a $50.00 price target on the stock. Separately, analysts at Leerink Swann raised their price target on shares of KYTHERA Biopharmaceuticals (NASDAQ:KYTH) from $28.00 to $34.00 in a research note to investors on Wednesday, August 7th. Finally, analysts at JPMorgan Chase & Co. raised their price target on shares of KYTHERA Biopharmaceuticals (NASDAQ:KYTH) from $30.00 to $34.00 in a research note to investors on Wednesday, August 7th.
Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. KYTHERA Biopharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $34.60.
Shares of KYTHERA Biopharmaceuticals (NASDAQ:KYTH) traded up 2.34% on Tuesday, hitting $32.74. 210,405 shares of the company’s stock traded hands. KYTHERA Biopharmaceuticals has a 52 week low of $14.07 and a 52 week high of $32.00. The stock has a 50-day moving average of $26.51 and a 200-day moving average of $24.55. The company’s market cap is $610.3 million.
KYTHERA Biopharmaceuticals (NASDAQ:KYTH) last announced its earnings results on Tuesday, August 6th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.03. On average, analysts predict that KYTHERA Biopharmaceuticals will post $-2.97 earnings per share for the current fiscal year.
KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.